Molecular Formula | C4H4FeO4 |
Molar Mass | 171.91716 |
Author:
Abstract:
objective: to observe the therapeutic effect of Ferrous Succinate Tablets on pregnancy complicated with iron deficiency anemia (IDA) and its effect on hemoglobin (Hb), red blood cell (RBC) and serum ferritin (SF). Methods 120 cases of pregnancy complicated with iron deficiency anemia in our hospital from January 2011 to December 2012 were selected (all met the inclusion criteria), including 107 cases of mild anemia, 13 cases of moderate anemia, 0 cases of severe anemia, patients were given oral Ferrous Succinate Tablets, 1-2 tablets/time, 3 times/d. Hb,RBC and SF of pregnant women were measured before and after treatment. The adverse reactions during the experiment were observed and recorded, and the safety of the drug was evaluated. Results 120 cases of pregnancy with iron deficiency anemia in patients with 39 cases were cured, 57 cases were markedly effective, 22 cases were effective, 2 cases were invalid, the total effective rate was 98.3%. There were significant differences in Hb,RBC and SF between before and after treatment (P<0.01). During the treatment, some patients had mild adverse reactions, which did not affect the therapeutic effect. Conclusion Ferrous Succinate Tablets has a significant therapeutic effect on pregnancy complicated with iron deficiency anemia, which can significantly improve the Hb,RBC and SF of patients with pregnancy complicated with iron deficiency anemia.
expand
Key words:
Ferrous Succinate Tablets pregnancy iron deficiency anemia
DOI:
CNKI:SUN:LYLC.0.2014-05-036
cited:
year:
2014
Author:
Abstract:
Objective to investigate the effect of shengxuening tablets and ferrous succinate on renal anemia in hemodialysis (MHD) patients. Methods 60 hemodialysis patients with renal anemia were randomly divided into two groups, 30 cases in each group. D1 group was orally administered with 3 secondary Xuening tablets, 0.5g each time; D2 group was orally administered with ferrous succinate 3 times a day, 0.2g each time. Both groups were given combined subcutaneous injection of erythropoietin (EPO). After 12 weeks of treatment, the clinical efficacy, hemoglobin (Hb), hematocrit (Hct), serum ferritin (SF), transferrin saturation (TSAT) of two groups were observed and compared before and after treatment. And changes in nutrition-related indicators and adverse reactions. Results The total effective rate of D1 group and D2 group was 90.00%(P 〈 0.05), SF and TSAT levels were significantly higher than D2 group (P 〈 0.05),EPO dosage was significantly lower than D2 group (P 〈 0.05);D1 group after treatment weight, Alb,Scr,BUN,DPI, the levels of DEI and nPNA were significantly higher than those in D2 group (P 〈 0.05). The total adverse reaction rate of D1 group was 6.67%, which was significantly lower than 13.33% of D2 group (P 〈 0.05). Conclusion Both shengxuening and ferrous succinate can effectively improve anemia, iron metabolism and malnutrition in hemodialysis patients, but shengxuening has better effect, lower adverse reaction rate and higher safety than ferrous succinate.expand
Key words:
hemodialysis; Renal anemia; Shengxuening tablets; ferrous succinate
DOI:
10.3969/j.issn.1006-4931.2013.09.004
cited:
year:
2013
Author:
Ding Runsheng , Jiang Shenghua
Abstract:
42 cases of iron deficiency anemia patients were randomly divided into two groups, respectively, the application of ferrous succinate granules and tablets to observe its curative effect. The results showed that the two groups had obvious clinical curative effect, the effective rate was 100%. There were no obvious side effects, liver, kidney and heart function damage. After 4 weeks, Hb,RBC and SF increased significantly, but the increase of SF should reach normal level in more than 6 weeks. Two different forms of ferrous succinate were effective in the treatment of iron deficiency anemia.
Key words:
ferrous succinate hemoglobin iron deficiency anemia treatment
DOI:
CNKI:SUN:JTYX.0.1998-02-022
cited:
year:
1998
Author:
Yue Xiangyang , Jin Pengfei , Cao Guoying Hu Xin , chanle plum , Kexin Li , Huang Chunxin , Wang Weihong
Abstract:
Objective: to study the pharmacokinetics and bioequivalence of ferrous succinate tablets in healthy volunteers. Methods: according to the randomized crossover design, 20 healthy male subjects were given a single oral dose of 200 mg, and then the serum iron concentration was determined by inductively coupled plasma mass spectrometry (ICP-MS), the main pharmacokinetic parameters were calculated by BAPP 3.0 software. Results: the Cmax of the reference and test preparations were (3028.25±707.44) and (2986.50±621.07)μg, respectively. L-1;Tmax were (3.7±1.3) and (4.3±1.6)h;t1/2 were (27.66±27.38) and (32.91±32.62)h;AUC0 ~ & tau; Respectively (48394.09±8419.76) and (48459.73±9242.03)μg.h.L-1;AUC0 ~ ∞ were (81768.39±33624.43) and (91477.34±48827.18)μg, respectively. h.L-1. Conclusion: The two ferrous succinate tablets are bioequivalent by statistical test.Key words:
inductively coupled plasma mass spectrometry ferrous succinate pharmacokinetics bioequivalence
DOI:
CNKI:SUN:YWFX.0.2011-02-035
cited:
year:
2011
Author:
Abstract:
objective to compare the efficacy of ferrous succinate and ferrous sulfate in the treatment of iron deficiency anemia in children. Methods 72 cases of children with iron deficiency anemia admitted to Department of Pediatrics of Cao County Hospital from January 2010 to December 2012 were selected as the research objects. The children were divided into ferrous succinate group (treated with ferrous succinate) by random number table method. And ferrous sulfate group (treated with ferrous sulfate), 36 cases in each group. After 3 months of treatment, the clinical efficacy, serological indexes and adverse reactions of the two groups were compared. Results compared with ferrous sulfate group, the effect of ferrous succinate group was better, hemoglobin and serum ferritin increased more significantly, and the incidence of adverse reactions was lower (P0.05). Conclusion ferrous succinate is effective in the treatment of ischemic anemia with less adverse reactions.
Key words:
pediatric iron deficiency anemia ferrous succinate ferrous sulfate
DOI:
CNKI:SUN:YXZS.0.2015-03-068
cited:
year:
2015
utility model
Application (patent) number:
CN201920993648.1
application date:
20190628
Public/Announcement Number:
CN210963060U
Public/announcement date:
20200710
applicant (patent):
Chengdu aobang Pharmaceutical Co., Ltd.
inventor:
clear , Wei Lan , Zhang Yinglong , Gao Bei
National and provincial code:
CN510183
Abstract:
The utility model discloses a mobile layer coating machine for Ferrous Succinate Tablets, comprising a base, a box body and a drum, wherein the box body is fixedly connected to the base body, and the drum body is rotatably connected to the box body, the roller is connected with a dial plate, the top of the box body is connected with a support frame, the top of the support frame is connected with a mixing box, and the top of the mixing box is connected with a first motor, an output end of the first motor is connected with a stirring part, a first strut is fixedly connected to the support frame, and one end of the first strut far away from the support frame is rotationally connected with a second strut, one end of the second strut far away from the first strut is connected to the nozzle by rotating, a blower is connected in the box body, a duct is connected to the blower, and one end of the duct far away from the blower is located in the drum, the utility model has the advantages of low cost, high efficiency, and improved pharmaceutical uniformity.